Pfizer Uses HCA for Hepatotox Assay, Seeks to Expand Tox Prediction Toolbox | GenomeWeb
SAN FRANCISCO — Pfizer researchers have used high-content imaging to develop a cellular hepatotoxicity screen that it will use for certain in vitro drug-development studies.
Pfizer’s existing toxicology portfolio comprises micronucleus assays and phospholipidosis assays. Now it plans to add to this mix hepatotoxicity assays, which will enable the company to focus narrowly on the way a single organ responds to drug candidates.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.